Clinical Trial Update: A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for C105 assessing cognitive dysfunction in persons with multiple sclerosis; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders
• Multiple Sclerosis

Drugs mentioned

• C105 (C105)

Snippet

Sponsor: Cognition Pharmaceuticals, LLC | Conditions: Cognition Disorders, Multiple Sclerosis | Phase 2 | Status: COMPLETED